Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis

Krystal Biotech (Nasdaq:KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to the company’s gene therapy candidate KB105, for the treatment of patients with TGM-1-deficient autosomal recessive congenital ichthyosis. As […]